Jupiter Life Line Hospitals Q4 Results: Net Profit at 506M Rupees, Revenue Rises to 3.9B Rupees

Jupiter Life Line Hospitals Limited has reported its audited consolidated financial results for Q4, with net profit rising to 506 million rupees compared to 449 million rupees in the same period last year. Revenue for the quarter grew to 3.9 billion rupees from 3.3 billion rupees year-on-year, reflecting steady operational growth. The results were taken up at the board meeting held on Friday, May 15, 2026, as previously scheduled pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Q4 Financial Performance

Jupiter Life Line Hospitals delivered a consistent financial performance in Q4, with growth recorded across key metrics. The following table presents a snapshot of the consolidated Q4 results:

Metric: Q4 Current Q4 Previous (YoY) Net Profit: 506M Rupees 449M Rupees Revenue: 3.9B Rupees 3.3B Rupees EBITDA: 907M Rupees 782M Rupees EBITDA Margin: 23.39% 23.94%

EBITDA for the quarter stood at 907 million rupees versus 782 million rupees in the year-ago period, indicating improved absolute operating profitability. However, the EBITDA margin moderated slightly to 23.39% from 23.94% year-on-year, reflecting a marginal compression in operating efficiency relative to revenue growth.

Board Meeting Agenda

Along with the financial results, the board meeting convened to deliberate on several significant corporate matters. The key agenda items are summarised below:

Agenda Item: Details Financial Results: Audited Standalone and Consolidated results for Q4 and FY ended March 31, 2026 Interim Dividend: Consideration and declaration of interim dividend on equity shares for FY 2025-26 Share Split Proposal: Sub-division/split of equity shares with face value of Rs. 10 each, fully paid up Record Date (Dividend): Friday, May 22, 2026

Interim Dividend and Share Split

In terms of Regulation 42 of the Listing Regulations, the company has set Friday, May 22, 2026 as the record date for determining shareholders entitled to receive the interim dividend for FY 2025-26, if declared by the Board of Directors. The board also considered a proposal for the sub-division/split of existing equity shares having a face value of Rs. 10 each, fully paid up. The manner of the split will be determined by the Board of Directors, subject to shareholder approval and other requisite regulatory approvals.

Trading Window Closure

In accordance with the Company's Code of Conduct for Prevention, Regulation, Monitoring and Reporting of Insider Trading under the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window will remain closed for all Designated Persons and their Immediate Relatives until 48 hours from the conclusion of the board meeting. The intimation has been filed with the National Stock Exchange of India Ltd. and BSE Limited, and will also be made available on the company's website at www.jupiterhospital.com , pursuant to Regulation 46(2) of the Listing Regulations. The notice was signed by Suma Upparatti, Company Secretary & Compliance Officer, on May 11, 2026.

Jupiter Life Line Hospitals Limited has informed the stock exchanges of the resignation of Dr. Bhaskar Shah (DIN: 00007817) from the position of Non-Executive Non-Independent Director, with immediate effect. The resignation letter was dated May 14, 2026, with Dr. Bhaskar Shah citing preoccupancy and professional commitments as the reason for his departure. The disclosure was made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Resignation Details

The company filed the requisite disclosure in compliance with SEBI Circular no. SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The intimation was submitted to both the National Stock Exchange of India Ltd. and BSE Limited on May 15, 2026. The key details of the change in directorship are outlined below:

Parameter: Details Director Name: Dr. Bhaskar Shah DIN: 00007817 Designation: Non-Executive Non-Independent Director Reason for Change: Resignation due to preoccupancy and professional commitments Effective Date: May 14, 2026 Brief Profile (Appointment): Not Applicable Relationship Disclosure (Appointment): Not Applicable

Regulatory Compliance

The intimation was filed by Suma Upparatti, Company Secretary and Compliance Officer of Jupiter Life Line Hospitals Limited, on May 15, 2026. The company has stated that the relevant disclosure will also be made available on its official website at www.jupiterhospital.com . The filing confirms the company's adherence to its disclosure obligations under the applicable listing regulations.

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.

As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.

We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.

This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.

The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.

We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.

This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.

By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.

We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.